SCHEMBL27218692

SCHEMBL27218692

Oc1cc(C(F)(F)F)nc(SCCc2ncc(-c3ccccc3)o2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.43
▸ RXRA P19793 1/20 0.43
▸ RXRB P28702 1/20 0.43
▸ RXRG P48443 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ HDAC3 O15379 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HDAC9 Q9UKV0 1/20 0.39
▸ HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29807857 0.84 NOTUM (0.43) NOTUMRXRARXRBRXRGALDH1A1
SCHEMBL27218724 0.83 ALDH1A1 (0.43) NOTUMRXRARXRBRXRGALDH1A1
SCHEMBL27218937 0.79 ALDH1A1 (0.40) NOTUMRXRARXRBRXRGALDH1A1
SCHEMBL27218779 0.79 ALDH1A1 (0.42) NOTUMALDH1A1SMN1; SMN2MAPK1L3MBTL1
SCHEMBL27218940 0.78 FFAR1 (0.40) NOTUMALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL27218723 0.76 MAPT (0.48) ALDH1A1SMN1; SMN2MAPK1L3MBTL1POLB
SCHEMBL27218819 0.76 VCP (0.42) ALDH1A1SMN1; SMN2MAPK1L3MBTL1POLB
SCHEMBL27218694 0.76 HDAC1 (0.49) NOTUMALDH1A1SMN1; SMN2MAPK1L3MBTL1
SCHEMBL27218736 0.75 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2L3MBTL1POLBHDAC1
SCHEMBL27218749 0.73 POLB (0.39) NOTUMALDH1A1SMN1; SMN2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 NOTUM 1725/4885RXRA 331/4885RXRB 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback